Handelsbanken Fonder’s Allogene Therapeutics ALLO Stock Holding History

Handelsbanken Fonder’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,700	Closed	-$137K	–	1560
2022 Q3	$137K	Hold	12,700	–	–	﹤0.01%	1494
2022 Q2	$145K	Hold	12,700	–	–	﹤0.01%	1542
2022 Q1	$116K	Hold	12,700	–	–	﹤0.01%	1681
2021 Q4	$189K	Hold	12,700	–	–	﹤0.01%	1713
2021 Q3	$326K	Hold	12,700	–	–	﹤0.01%	1567
2021 Q2	$331K	Buy	12,700 +1,000	+9%	+$28.5K	﹤0.01%	1601
2021 Q1	$413K	Hold	11,700	–	–	﹤0.01%	1295
2020 Q4	$295K	Hold	11,700	–	–	﹤0.01%	1413
2020 Q3	$441K	Hold	11,700	–	–	﹤0.01%	1050
2020 Q2	$501K	Buy	+11,700	New	+$423K	﹤0.01%	959

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Handelsbanken Fonder's ALLO Position: Q4 2022 in Review

Handelsbanken Fonder sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 12,700 shares — an estimated $137K sold.

Handelsbanken Fonder first reported a position in ALLO in Q2 2020 and held it in 10 quarters. The position peaked at $501K in Q2 2020. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

Handelsbanken Fonder reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
Handelsbanken Fonder sold 12,700 Allogene Therapeutics shares in Q4 2022, an estimated $137K.
Handelsbanken Fonder first reported a position in Allogene Therapeutics in Q2 2020 and held it in 10 quarters.
Handelsbanken Fonder's Allogene Therapeutics position peaked at $501K in Q2 2020.
168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Handelsbanken Fonder's 13F filing for Q4 2022, filed 7 Feb 2023.